Heilongjiang ZBD Pharmaceutical Valuation

Q: What is the Fair Price of 603567 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

603567 (CN¥12.39) is trading above our estimate of [[fair value]] (CN¥4.27)

Is 603567 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603567 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603567 (CN¥12.39) is trading above our estimate of fair value (CN¥4.27)

Significantly Below Fair Value: 603567 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603567?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 603567. This is calculated by dividing 603567's market cap by their current preferred multiple.
What is 603567's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥11.64b

603567 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.4x
Enterprise Value/EBITDA	14.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 603567's PE Ratio compare to its peers?

The above table shows the PE ratio for 603567 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	33.6x
300026 Tianjin Chase Sun PharmaceuticalLtd	39.6x	23.2%	CN¥12.2b
600993 Mayinglong Pharmaceutical Group	24.8x	n/a	CN¥11.8b
600422 KPC PharmaceuticalsInc	26.6x	26.9%	CN¥12.0b
002626 Xiamen Kingdomway Group	43.3x	35.5%	CN¥9.7b
603567 Heilongjiang ZBD Pharmaceutical	15.3x	n/a	CN¥11.6b

Price-To-Earnings vs Peers: 603567 is good value based on its Price-To-Earnings Ratio (15.3x) compared to the peer average (33.6x).

Price to Earnings Ratio vs Industry

How does 603567's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.5%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.5%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 603567 is good value based on its Price-To-Earnings Ratio (15.3x) compared to the CN Pharmaceuticals industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is 603567's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603567 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	15.3x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 603567's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.